Oct 13 (Reuters) - Dermira Inc:
* Dermira highlights new long-term safety data for glycopyrronium tosylate in primary axillary hyperhidrosis at fall clinical dermatology conference
* Dermira Inc - daily treatment with glycopyrronium tosylate in Phase 3, open-label arido trial was generally well-tolerated
* Dermira - efficacy assessment suggests sweat reduction levels were maintained in patients treated with glycopyrronium tosylate during extended study Source text for Eikon: Further company coverage:
